Allelic prevalence and geographic distribution of cerebrotendinous xanthomatosis.
Allele frequency
Cerebrotendinous xanthomatosis (CTX)
Genomic variation
Pathogenic variants
Rare metabolic disease
Journal
Orphanet journal of rare diseases
ISSN: 1750-1172
Titre abrégé: Orphanet J Rare Dis
Pays: England
ID NLM: 101266602
Informations de publication
Date de publication:
17 01 2023
17 01 2023
Historique:
received:
08
08
2022
accepted:
20
11
2022
entrez:
17
1
2023
pubmed:
18
1
2023
medline:
20
1
2023
Statut:
epublish
Résumé
Cerebrotendinous xanthomatosis (CTX) is a rare recessive genetic disease characterized by disruption of bile acid synthesis due to inactivation of the CYP27A1 gene. Treatment is available in the form of bile acid replacement. CTX is likely underdiagnosed, and prevalence estimates based on case diagnosis are probably inaccurate. Large population-based genomic databases are a valuable resource to estimate prevalence of rare recessive diseases as an orthogonal unbiased approach building upon traditional epidemiological studies. We leveraged the Hardy-Weinberg principle and allele frequencies from gnomAD to calculate CTX prevalence. ClinVar and HGMD were used to identify high-confidence pathogenic missense variants and to calculate a disease-specific cutoff. Variant pathogenicity was also assessed by the VarSome implementation of the ACMG/AMP algorithm and the REVEL in silico predictor. CTX prevalence estimates were highest in Asians (1:44,407-93,084) and lowest in the Finnish population (1:3,388,767). Intermediate estimates were found in Europeans, Americans, and Africans/African Americans (1:70,795-233,597). The REVEL-predicted pathogenic variants accounted for a greater increase in prevalence estimates for Europeans, Americans, and Africans/African Americans compared with Asians. We identified the most frequent alleles designated pathogenic in ClinVar (p.Gly472Ala, p.Arg395Cys), labeled pathogenic based on sequence consequence (p.Met1?), and predicted to be pathogenic by REVEL (p.Met383Lys, p.Arg448His) across populations. Also, we provide a prospective geographic map of estimated disease distribution based on CYP27A1 variation queries performed by healthcare providers from selected specialties. Prevalence estimates calculated herein support and expand upon existing evidence indicating underdiagnosis of CTX, suggesting that improved detection strategies are needed. Increased awareness of CTX is important for early diagnosis, which is essential for patients as early treatment significantly slows or prevents disease progression.
Sections du résumé
BACKGROUND
Cerebrotendinous xanthomatosis (CTX) is a rare recessive genetic disease characterized by disruption of bile acid synthesis due to inactivation of the CYP27A1 gene. Treatment is available in the form of bile acid replacement. CTX is likely underdiagnosed, and prevalence estimates based on case diagnosis are probably inaccurate. Large population-based genomic databases are a valuable resource to estimate prevalence of rare recessive diseases as an orthogonal unbiased approach building upon traditional epidemiological studies.
METHODS
We leveraged the Hardy-Weinberg principle and allele frequencies from gnomAD to calculate CTX prevalence. ClinVar and HGMD were used to identify high-confidence pathogenic missense variants and to calculate a disease-specific cutoff. Variant pathogenicity was also assessed by the VarSome implementation of the ACMG/AMP algorithm and the REVEL in silico predictor.
RESULTS
CTX prevalence estimates were highest in Asians (1:44,407-93,084) and lowest in the Finnish population (1:3,388,767). Intermediate estimates were found in Europeans, Americans, and Africans/African Americans (1:70,795-233,597). The REVEL-predicted pathogenic variants accounted for a greater increase in prevalence estimates for Europeans, Americans, and Africans/African Americans compared with Asians. We identified the most frequent alleles designated pathogenic in ClinVar (p.Gly472Ala, p.Arg395Cys), labeled pathogenic based on sequence consequence (p.Met1?), and predicted to be pathogenic by REVEL (p.Met383Lys, p.Arg448His) across populations. Also, we provide a prospective geographic map of estimated disease distribution based on CYP27A1 variation queries performed by healthcare providers from selected specialties.
CONCLUSIONS
Prevalence estimates calculated herein support and expand upon existing evidence indicating underdiagnosis of CTX, suggesting that improved detection strategies are needed. Increased awareness of CTX is important for early diagnosis, which is essential for patients as early treatment significantly slows or prevents disease progression.
Identifiants
pubmed: 36650582
doi: 10.1186/s13023-022-02578-1
pii: 10.1186/s13023-022-02578-1
pmc: PMC9843874
doi:
Substances chimiques
Bile Acids and Salts
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
13Informations de copyright
© 2023. The Author(s).
Références
J AAPOS. 2021 Oct;25(5):269.e1-269.e6
pubmed: 34600103
Orphanet J Rare Dis. 2020 Nov 18;15(1):324
pubmed: 33208168
Nature. 2020 May;581(7809):434-443
pubmed: 32461654
J Lipid Res. 2017 May;58(5):1002-1007
pubmed: 28314860
Neurology. 2019 Jan 8;92(2):61-62
pubmed: 30530794
Neurol Sci. 2017 Mar;38(3):481-483
pubmed: 27888347
N Engl J Med. 1987 May 14;316(20):1233-8
pubmed: 3106810
Hum Genet. 2015 Jun;134(6):659-69
pubmed: 25893794
Clin Neuropharmacol. 2013 May-Jun;36(3):78-83
pubmed: 23673909
JIMD Rep. 2021 Jan 08;59(1):3-9
pubmed: 33977023
Mol Genet Metab. 2019 Dec;128(4):463-469
pubmed: 31540697
Genet Med. 2017 Oct;19(10):1151-1158
pubmed: 28518168
Transl Psychiatry. 2013 Sep 03;3:e302
pubmed: 24002088
EBioMedicine. 2020 Apr;54:102730
pubmed: 32305867
Genet Med. 2020 Oct;22(10):1606-1612
pubmed: 32523054
Science. 1908 Jul 10;28(706):49-50
pubmed: 17779291
Ann Hum Genet. 2020 Nov;84(6):463-468
pubmed: 32484936
Genet Med. 2019 May;21(5):1155-1163
pubmed: 30254379
Brain. 2000 May;123 ( Pt 5):908-19
pubmed: 10775536
Curr Opin Lipidol. 2021 Apr 1;32(2):123-131
pubmed: 33630770
J Lipid Res. 2014 Jan;55(1):146-54
pubmed: 24186955
J Inherit Metab Dis. 2018 Jul;41(4):647-656
pubmed: 29484516
N Engl J Med. 2015 Jun 4;372(23):2235-42
pubmed: 26014595
Genet Med. 2018 Sep;20(9):1054-1060
pubmed: 29300386
J Inherit Metab Dis. 2018 Jul;41(4):641-646
pubmed: 28894950
Eur J Hum Genet. 2021 Aug;29(8):1186-1197
pubmed: 33854215
Biochem Biophys Res Commun. 2010 May 21;396(1):46-9
pubmed: 20494109
J Inherit Metab Dis. 2014 May;37(3):421-9
pubmed: 24442603
BMC Health Serv Res. 2020 Mar 6;20(1):183
pubmed: 32143624
Genet Med. 2015 May;17(5):405-24
pubmed: 25741868
Clin Genet. 2022 Feb;101(2):190-207
pubmed: 34689324
J Inherit Metab Dis. 2017 Nov;40(6):771-781
pubmed: 28980151
J Inherit Metab Dis. 2018 Sep;41(5):799-807
pubmed: 29560583
JAMA Ophthalmol. 2019 Nov 01;137(11):1312-1316
pubmed: 31536098
Genet Med. 2020 Nov;22(11):1812-1820
pubmed: 32665702
Mol Genet Metab Rep. 2020 Jun 05;24:100602
pubmed: 32528851
Am J Hum Genet. 2016 Oct 6;99(4):877-885
pubmed: 27666373
Genet Med. 2017 Oct;19(10):1096-1104
pubmed: 28301460
Orphanet J Rare Dis. 2021 Aug 6;16(1):353
pubmed: 34362411
Orphanet J Rare Dis. 2014 Nov 26;9:179
pubmed: 25424010
Neurodegener Dis. 2019;19(5-6):218-224
pubmed: 32349000
Sci Transl Med. 2016 Jan 20;8(322):322ra9
pubmed: 26791950
J Hepatol. 2019 Jan;70(1):142-150
pubmed: 30315827
N Engl J Med. 1984 Dec 27;311(26):1649-52
pubmed: 6504105
Neurology. 2019 Jan 8;92(2):e83-e95
pubmed: 30530799
J Intern Med. 2021 Nov;290(5):1039-1047
pubmed: 33830582
Brain. 2013 May;136(Pt 5):1476-87
pubmed: 23518715
Mol Genet Metab. 2015 Dec;116(4):298-304
pubmed: 26643207
Arch Neurol. 2000 Apr;57(4):520-4
pubmed: 10768627